Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
Japan will resume a cost-effectiveness assessment (CEA) of Novartis Pharma’s spinal muscular atrophy (SMA) gene therapy Zolgensma (onasemnogene abeparvovec), following a five-year suspension to collect long-term efficacy data. The Central Social Insurance Medical Council (Chuikyo) approved the resumption at its…
To read the full story
Related Article
REGULATORY
- Mumps Shots Gain Strong Backing as Japan Weighs FY2027 NIP Priorities
November 20, 2026
- Lilly’s Oral GLP-1 Obesity Drug Heads to Dec. 2 Panel Review, Eyes Japan First
November 19, 2026
- Pharma Prods LDP to Rethink CEA Expansion, Project Team to Compile Proposal
November 19, 2026
- First Pralia Biosimilars Inching Closer to Japan Approval, 5 Products Lined Up
November 19, 2026
- MHLW Drug Supply Monitoring System Hit by Cyberattack, Possible Data Leak
November 19, 2026





